期刊文献+

造血干细胞移植后植入状态的评价 被引量:3

下载PDF
导出
摘要 异基因造血干细胞移植是治疗血液系统疾病、自身免疫性疾病和某些实体瘤的有效手段。移植后供体干细胞是否植活形成嵌合体及其动态演变过程不仅影响着疾病的转归,还对临床治疗具有重要的指导意义。用于判断移植后造血干细胞植活直接依据主要依赖于体内各种遗传标记。目前利用遗传标记对受者进行嵌合状态分析的方法有很多,可归为生化方法、细胞遗传学方法和分子遗传学方法三类。本文就目前常用的嵌合体分析方法作一综述。
出处 《国外医学(内科学分册)》 2003年第3期118-122,共5页 Foreign Medical Sciences(Section of Internal Medicine)
  • 相关文献

参考文献25

  • 1[2]Choi SJ ,Lee KH, Lee JH, et al. [J]. Bone Marrow Transplant, 2000,26: 327-332.
  • 2[3]Thiede C, Florek M, Bornhauder M, et al. [J]. Bone Marrow Transplant, 1999,23:1055-1060.
  • 3[4]Bader P, Back J, Frey A, et al. [J]. Bone Marrow Transplant, 1998,21:487-495.
  • 4[5]Serrano J, Roman J, Herrera C, et al. [J]. Bone Marrow Transplant, 1999,23:475-482.
  • 5[6]de Man AJ, Foolen WJ, van Dijk BA, et al. [J]. Vox Sang, 1988,55:37-41.
  • 6[7]Schaap N, Schattenberg A, Bar B, et al. [J]. Br J Haematol, 2000,108(1): 116-125.
  • 7[8]Bruce R, Blazar, Orr HT, et al. [J]. Blood, 1985,66(6): 1436-1444.
  • 8[9]Frankel W, Chan A, Corringham RET, et al. [J].Am J Hematol, 1996,52:281-287.
  • 9[10]Witherspoon RP, Schanfield MS, Storb R, et al. [J].Transplantation, 1978,26:407-408.
  • 10[12]Durnam DM, Anders KR, Fisher L, et al. [J].Blood, 1989,74:2220-2226.

同被引文献18

  • 1Prigozhina T,Gurevitch O,Slavin S.Non-myeloablative conditioning to induce tolerance after allogeneic bone marrow transplantation in mice.EXP Hematol,1999,27:1503.
  • 2Carella AM,Cavaliere M,Lerma E,et al.Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.Clin Oncol.2000,18:3918.
  • 3Carella AM,Cavaliere M,Lerma E,et al.Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and nonHodgkin's lymphoma.J Clin Oncol,2000,18:3918.
  • 4Rini BI,Halabi S,Barrier R.Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma:a CALGB intergroup phase Ⅱ study.Biol Blood Marrow Transplant,2006,12:778.
  • 5Slavin S,Nagler A,Naparstek E,et al.Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nomalignant hematolngic diseases.Blood,1998,91:756.
  • 6McWeeney P,Niederwieser D,Shizuru J,et al.Molecular remission after non-myeloablative allografting for chronic myelocytic leukemia.Blood,1999,94:710.
  • 7Khouri I,Keating M,Korbling M,et al.Transplant lite:induction of graft-versus-leukemia using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignances.J Clin Oncol,1998,16:2817.
  • 8Carella AM, Champlin R, Slavin S ,et al. Mini-allografts: ongoing trials in humans [J].Bone Marrow Transplant, 2000, 25 (4) : 345 -350
  • 9Slavin S, Or R, Aker M, et al. Nonmyeloablative stem cell transplantation for the treatment .of cancer and life-threatening non- malignant disorders: past accomplishments and future goals [J]. Cancer Chemother Pharmacol, 2001, 48 Suppl 1:S79-S84
  • 10Arellano ML, Langston A, Winton E, et al. Treatlnent of Relapsed Acute Leukemia after Allogeneic Transplantation:A Single Center Experience [ J ]. Biol Blood Marrow Transplant ,2007,13 ( 1 ) : 116-123

引证文献3

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部